<DOC>
	<DOCNO>NCT00773383</DOCNO>
	<brief_summary>This single arm study patient advance Stage IIIb/IV NSCLC progressive disease derive clinical benefit ( define response stable disease 12 week ) second third line Tarceva monotherapy determine proportion patient progression-free survival 12 week follow combination therapy R1507 Tarceva . Patients receive R1507 ( 9mg/kg iv ) weekly combination Tarceva ( 150mg oral daily ) maximum 24 month . Other disease-related endpoint include overall survival , objective response rate , time response , time progressive disease duration response also evaluate . The anticipated time study treatment 1-2 year , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Effect R1507 Combination With Tarceva ( Erlotinib ) Progression-Free Survival Patients With Stage IIIb/IV Non-Small Cell Lung Cancer ( NSCLC ) Having Received Tarceva Monotherapy .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>male female patient &gt; =18 year histologically document inoperable , locally advanced metastatic ( stage IIIB IV ) NSCLC ; currently receive Tarceva monotherapy fail least one standard chemotherapy regimen ; prior response stable disease 12 week start Tarceva ; document progressive disease enrollment ; measurable disease accord RECIST criterion ; ECOG performance status 02 ; life expectancy &gt; 12 week . patient active CNS lesion ; prior treatment agent act via IGF1R inhibition EGFR targeting ; administration high dos systemic corticosteroid ; radiotherapy 4 week prior study start ; surgery significant traumatic injury last 2 week prior study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>